Peptides are not a shortcut
These treatments use the active ingredient botulinum toxin type A, a type of neurotoxin that blocks communication between the facial muscles and nerves
By the time most patients notice visible changes in skin texture, hair density, or how quickly they recover from injury, the peptide that was quietly managing those processes has been declining for years
Without those findings, the elevation is better weighed against the broader metabolic picture and any comorbidities
For cardiovascular applications, this steadier exposure might provide more stable vascular effects compared to once-daily peaks and troughs
Primary research applications include Alzheimer's disease, vascular dementia, age-related cognitive decline, and neurological recovery after brain injury